Overview

Sequential Therapy in Metastatic Renal Cell Carinoma

Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
Sequential therapy with BEvacizumab, RAd001 (everolimus) and Tyrosinekinase inhibitors (TKI) in metastatic renal cell carcinoma (mRCC)
Phase:
Phase 2
Details
Lead Sponsor:
Central European Society for Anticancer Drug Research
Treatments:
Bevacizumab
Everolimus
Interferon alpha-2
Interferon-alpha
Sirolimus
Sorafenib
Sunitinib